Shelley Banks

• Administered patient care procedures, ensuring adherence to best practices and safety protocols.
• Managed electronic health records, maintaining accuracy and confidentiality of sensitive information.
• Educated patients on treatment plans and medication management to promote compliance and health outcomes.
• Collaborated with multidisciplinary teams to streamline processes and improve overall patient care delivery.
• Maintained strict confidentiality while handling sensitive patient information in accordance with HIPAA guidelines.
• Assisted physicians with various medical procedures and minor surgeries enhancing patient experience and workflow efficiency.
• Supported diagnostic processes with proficient collection of specimen samples for laboratory testing purposes.
• Coordinated administrative tasks such as scheduling appointments, updating records, and referrals.
• Strengthened patient-provider relationships through compassionate communication and attentive listening skills.
• Ensured accurate billing by diligently verifying insurance information for each patient visit.
• Performed medical records management, including filing, organizing and scanning documents
• Completed thorough chart reviews to ensure proper documentation of all pertinent medical information.

Research
ARMARON: To evaluate the efficacy, safety and tolerability of NP202 in adults who have
LVSD following an MI.
BEAT – HF: A clinical study to evaluate the safety and efficacy of Baroreflex Activation
Therapy with the Barostim Neo system in subjects with heart failure.
BEST: A double blind placebo controlled study to evaluate the effects of bexagliflozin on
Hemoglobin A1C in patients with type 2 diabetes and increased risk of cardiovascular
adverse events.
CAMELLIA ~ TIMI 61: A Randomized, double-blind placebo-controlled, parallel-group study
to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCL) on the incidence
of major adverse cardiovascular events and conversion to Type 2 Diabetes Mellitus in
obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk
factors.
CANTOS: A randomized, double-blind placebo-controlled, event driven trial of quarterly
subcutaneous canakinumab in the prevention of recurrent cardiovascular events among
stable post-myocardial infarction patients with elevated hsCRP.
CANTOS-OLE: An open-label extension study (OLE) toaccess the long-term safety and
efficacy of subcutaneous canakinumab.
Dal-GENE: A Phase II, double-blind randomization to evaluate the potential of dalcetrapib
on CV risk in genetically defined population with a recent ACS.
EXPERION CLEAR HARMONY: a Randomized, Double-blind, Placebo-controlled,
multicenter Long-term safety and Tolerability study of ETC-1002 in patients with
Hyperlipidemia at High Cardiovascular Risk who are not Adequately Controlled by their
Liquid-Modifying Therapy.
PARACHUTE: A structural heart study establishing efficacy and long-term safety of the
parachute device, implanted for poor LV function.
PARADISE MI: Evaluation of the efficacy and safety of LCZ696 compared to Ramipril in
high risk patients following an acute MI.
QUICKFLEX: Prospective, multicenter, non-randomized clinical study to evaluate the safety
and efficacy of the QuickFlex Micro Model 1258T left ventricular lead in a heart failure

patient population. The study will be conducted at a maximum of 20 investigational centers
located in the United States and a total of 68 patients will be enrolled.
Re-DUAL PCI: A randomized, open label, study to evaluate dual antithrombotic therapy
with dabigatran etexilate plus clopidogrel or ticagrelor vs. triple therapy strategy with
warfarin plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial
fibrillation that have undergone a percutaneous coronary intervention (PCI) with stenting.
REVEAL: A large-scale, randomized placebo-controlled trial of the clinical effects of
anacetrapib among people with established vascular disease.
SPIRE 1: Evaluation of the efficacy, safety and tolerability of BoCOcizumab (PF-
04950615), in reducing the occurrence of major cardiovascular events in high risk subjects.
SPIRE 2: Evaluation of the efficacy, safety and tolerability of BoCOcizumab (PF-
04950615), in reducing the occurrence of major cardiovascular events in high risk subjects.
VOYAGER: An international, multicenter randomized, double-blind, placebo – controlled
phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major
thrombotic vascular events in patients with symptomatic peripheral artery disease
undergoing lower extremity revascularization procedures.

• Prepared and administered medications to alleviate patient symptoms.
• Assisted physicians with various medical procedures, ensuring accurate results and timely treatment.
• Taught patients about medications, procedures, and care plan instructions.
• Collaborated with the healthcare team to create personalized care plans for patients.